Evidence map›Paper›PMID 40762797›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2026

Assessment of the diagnostic efficacy and clinical significance of [

Meixi Liu, Yuwei Zhang, Xinchun Yan, Haiqiong Zhang, Chao Ren, Zhenghai Huang, Yuejuan Cheng, Qiang Xu, Yatong Li, Ru Jia and 2 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06056362 (Evaluation of Biodistribution, Dosimetry, Diagnostic Ability, and Safety of Al18F-NOTA-LM3 in Patients With Well-differentiated Neuroendocrine Tumors, and Comparison With 68Ga-DOTATATE and 68Ga-NODAGA-LM3), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06056362 phase1 / phase2recruitingnot on this map

Evaluation of Biodistribution, Dosimetry, Diagnostic Ability, and Safety of Al18F-NOTA-LM3 in Patients With Well-differentiated Neuroendocrine Tumors, and Comparison With 68Ga-DOTATATE and 68Ga-NODAGA-LM3: A Prospective, Single-center, Double-blinded Study

TypeinterventionalSponsorPeking Union Medical College HospitalRan2023 to 2025Enrolled80ConditionsNeuroendocrine TumorsArmsAl18F-NOTA-LM3, 68Ga-DOTATATE, 68Ga-NODAGA-LM3
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Meixi Liu *Department of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Yuwei Zhang *Department of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Xinchun YanDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Haiqiong ZhangDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Chao RenDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Zhenghai HuangTheranostics and Translational Research Center, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yuejuan ChengDepartment of Oncology, Peking Union Medical College Hospital, Beijing, 100730, China.
Qiang XuDepartment of General Surgery, Peking Union Medical College Hospital, Beijing, 100730, China.
Yatong LiDepartment of Radiology, Peking Union Medical College Hospital, Beijing, 100730, China.
Ru JiaDepartment of Gastrointestinal Oncology, the fifth Medical Center, General Hospital of PLA, Beijing, China.
Wenjia ZhuDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. zhuwenjia_pumc@163.com.
Li HuoDepartment of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. huoli@pumch.cn.ORCID 0000-0003-1216-083X

Funding

Beijing Natural Science Foundation No. L242062Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences No. CIFMS-2023-I2M-2-002, CIFMS-2021-I2M-1-002, CIFMS-2021-I2M-1-003, CIFMS-2021-I2M-1-025, 2024-12M-ZD-001National High Level Hospital Clinical Research Funding No. 2022-PUMCH-D-001, 2022-PUMCH-D-002, 2022-PUMCH-B-072National Key R&D Program of China No. 2024YFC2419400, 2024YFC2419401National Natural Science Foundation of China No. U24A20758, 82071967, 82202218Peking Union Medical College Hospital Talent Cultivation Program Category D UHB12582
6 · The paper itself

Abstract

purposeThis study aimed to compare the diagnostic efficacy and clinical management impact of [

methodsPatients with histologically confirmed well-differentiated NETs were prospectively recruited and randomized into two arms: Arm A, undergo [

resultsA total of 78 patients were included in this study: 38 in Arm A and 40 in Arm B. [

conclusion[

trial registrationClinicalTrials.gov identifier NCT06056362.

Indexed as

AcetatesHeterocyclic CompoundsNeuroendocrine TumorsPositron Emission Tomography Computed TomographyAdultAgedClinical RelevanceFemaleFluorine RadioisotopesHeterocyclic Compounds, 1-RingHumansMaleMiddle AgedOrganometallic CompoundsRadiopharmaceuticalsTissue Distribution1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononaneAcetatesFluorine Radioisotopesgallium Ga 68 dotatateHeterocyclic CompoundsHeterocyclic Compounds, 1-RingOrganometallic CompoundsRadiopharmaceuticals[18F]AlF-NOTA-LM3[68Ga]Ga-DOTATATE[68Ga]Ga-NODAGA-LM3Neuroendocrine tumorSomatostatin receptor antagonist

Identifiers

PMID40762797

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.